Angitia Biopharmaceuticals, a Guangzhou-based developer of therapies for bone, joint, and muscle diseases, has announced the successful completion of a Series B+ phase II financing round, securing USD 40 million in funds. The round was led by YueKai Health Venture, with the proceeds earmarked to propel the global development of Angitia Bio’s innovative drug candidates AGA2118, AGA2115, and AGA111, which are aimed at addressing serious musculoskeletal disorders.
Specializing in the pathophysiology of bone and joint diseases, Angitia Bio harnesses advanced genetic and molecular biology techniques to uncover new mechanisms and signaling pathways, as well as their interactions, to identify new drug targets. The company is adept at combining computer-aided design for the development of both new biological drugs and small molecule chemical drugs, positioning itself at the forefront of musculoskeletal disorder treatment innovation.
This financing round not only underscores investor confidence in Angitia Bio’s approach but also highlights the significant potential of its pipeline in the musculoskeletal disease therapy space.- Flcube.com
